AZ 01 (peginterferon beta-1a biosimilar) / Allozyne - LARVOL DELTA

Allozyne looks to rustle up interest on Wall Street with backdoor IPO (Xconomy) - Allozyne after acquiring Poniard will be listed company and will have an IPO; The deal will happen only if Allozyne gets 2.2M approval votes from Poniard’s shareholders which might be cumbersome as Allozyne has an unknown background; Deal might happen in Q3 or Q4 2011; Positive data release of AZ01 and ability of AZ01 to match the market competition can win trust of Poniard shareholders

Stock market • Multiple Sclerosis

ALLOZYNE announces positive results from phase 1B trial of AZ01 (Marketwire) - P1B, N=NA, MAD; AZ01 has a comparable half-life after each administration and the half-life is two to three times longer than other PEGylated interferon beta; Overall AZ01 has been well tolerated and subjects dosed experienced typical symptoms associated with interferon beta treatment, most resolving within 24 hours; Study completion to be expected by YE 2011; Pivotal testing to be launched in 2012

Anticipated P1b study completion • P1b data • Multiple Sclerosis